{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06077877",
            "orgStudyIdInfo": {
                "id": "219590"
            },
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors",
            "officialTitle": "A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-the-safety-tolerability-pharmacokinetics-pk-and-preliminary-anticancer-activity-of-alone-or-with-niraparib-in-participants-with-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-11-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-05",
            "studyFirstSubmitQcDate": "2023-10-05",
            "studyFirstPostDateStruct": {
                "date": "2023-10-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasms"
            ],
            "keywords": [
                "POLQi",
                "Niraparib",
                "GSK4524101"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "This is an open-label non-blinded study"
                }
            },
            "enrollmentInfo": {
                "count": 135,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 - GSK4524101 Monotherapy",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4524101"
                    ]
                },
                {
                    "label": "Part 1 - GSK4524101 plus Niraparib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4524101",
                        "Drug: Niraparib"
                    ]
                },
                {
                    "label": "Part 1 - GSK4524101 Food Effect Cohort",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4524101"
                    ]
                },
                {
                    "label": "Part 2 - GSK4524101 plus Niraparib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK4524101",
                        "Drug: Niraparib"
                    ]
                },
                {
                    "label": "Part 2 - Niraparib",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Niraparib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GSK4524101",
                    "description": "GSK452101 will be administered.",
                    "armGroupLabels": [
                        "Part 1 - GSK4524101 Food Effect Cohort",
                        "Part 1 - GSK4524101 Monotherapy",
                        "Part 1 - GSK4524101 plus Niraparib",
                        "Part 2 - GSK4524101 plus Niraparib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Niraparib",
                    "description": "Niraparib will be administered.",
                    "armGroupLabels": [
                        "Part 1 - GSK4524101 plus Niraparib",
                        "Part 2 - GSK4524101 plus Niraparib",
                        "Part 2 - Niraparib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1 - Number of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation Period",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Part 1 - Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation Period",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation Period",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation Period",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation Period",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Part 2 - Confirmed Objective Response Rate (ORR)",
                    "description": "ORR is the percentage of participants with an Investigator-assessed confirmed complete response and confirmed partial response to treatment, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1",
                    "timeFrame": "Up to approximately 52 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1 - Area Under Curve (AUC) of GSK4364973 (Metabolite of GSK4524101)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 1 -Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 1 - Time to Maximum Concentration of GSK4364973 (Metabolite of GSK4524101)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 1 - Half-life of GSK4364973 (Metabolite of GSK4524101) (Days)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 1 -Plasma Concentration of Niraparib",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 1 - Number of Participants with TEAEs and SAEs based on Severity beyond DLT Observation Period",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Part 1 - Duration of TEAEs and SAEs (Days) beyond DLT Observation Period",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Part 2 - Number of Participants with TEAEs and SAEs based on Severity",
                    "timeFrame": "Up to approximately 52 weeks"
                },
                {
                    "measure": "Part 2 - Duration of Treatment Emergent AEs and SAEs (Days)",
                    "timeFrame": "Up to approximately 52 weeks"
                },
                {
                    "measure": "Part 2 - Progression-free Survival (PFS)",
                    "description": "PFS is time from randomization to progressive disease or death from any cause, whichever is earlier, as assessed via RECIST v1.1 by Investigator assessment",
                    "timeFrame": "Up to approximately 52 weeks"
                },
                {
                    "measure": "Part 2 - Duration of Response (DOR)",
                    "description": "DOR is defined as time from first documented PR or better to disease progression (as assessed by RECIST v1.1 by investigator assessment) or death whichever is earlier for participants who have achieved a CR or PR",
                    "timeFrame": "Up to approximately 52 weeks"
                },
                {
                    "measure": "Part 2 -Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 2 - Minimum Concentration (Cmin) of GSK4364973 (Metabolite of GSK4524101)",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Part 2 -Plasma Concentration of Niraparib",
                    "timeFrame": "Up to 21 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* More than or equal to (\u2265)18 years of age\n* Eastern cooperative oncology group (ECOG) class 0-2\n* Life expectancy of a minimum of 3 month\n* Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options.\n\nExclusion Criteria:\n\n* Participant has not recovered (i.e., to Grade less than or equal to \\[\u22641\\] or to baseline) from prior chemotherapy-induced AEs.\n* Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.\n* Participant has symptomatic uncontrolled brain or leptomeningeal metastases.\n* Participant has a known additional malignancy that progressed or required active treatment within the last 2 years\n* Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).\n* Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) \\>140 millimetres of mercury (mmHg) or diastolic BP \\>90 mmHg.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "GSK Clinical Trials",
                    "affiliation": "GlaxoSmithKline",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Pamela N. Munster",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Pasquale Benedetto",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Brian Van Tine",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Minal Barve",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Timothy Yap",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "David Sommerhalder",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Alexander I. Spira",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Quincy Chu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Arif Ali Awan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Philippe Bedard",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.",
            "accessCriteria": "Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",
            "url": "https://www.gsk.com/en-gb/innovation/trials/data-transparency/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000545685",
                    "term": "Niraparib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M289466",
                    "name": "Niraparib",
                    "asFound": "PEEP",
                    "relevance": "HIGH"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}